DIFFUSE LARGE B CELL LYMPHOMA

This study is testing an oral medication called selinexor for adults with an aggressive type of blood cancer (diffuse large B-cell lymphoma) that has come back or stopped responding to at least two prior treatments. The main goal is to see if the drug can shrink the cancer and fo…

This study is testing a three-drug combination for people with an aggressive type of B-cell lymphoma that has returned or not responded to prior treatment. The main goal is to see if a specific pre-treatment plan can better manage a common side effect called cytokine release synd…

This study is testing a specific type of stem cell transplant using donated umbilical cord blood to treat patients with serious blood cancers and disorders. The procedure involves high-dose chemotherapy and radiation to wipe out the patient's diseased bone marrow before infusing …

This study is testing whether adding a maintenance drug called acalabrutinib after cellular therapies (like stem cell transplants or CAR-T cell therapy) can help prevent aggressive lymphoma from returning in patients at very high risk of relapse. Researchers want to see if this e…

This study is testing whether adding an experimental drug called SHR-A1912 to standard chemotherapy works better for people with aggressive lymphoma that has returned or stopped responding to previous treatments. Researchers will compare the new combination against the standard t…

This study is testing the safety and effectiveness of a combination of five targeted drugs (called ViPOR) for adults whose B-cell lymphoma has come back or not improved after prior treatment. The goal is to see if this drug mix can control the cancer. Participants will receive th…

This early-stage study is testing a new oral medication called LP-168 in adults whose B-cell blood cancers have returned or not responded to prior treatments. The main goals are to find the highest safe dose and understand how the drug moves through the body. Researchers will als…

This study is testing a personalized cell therapy called axicabtagene ciloleucel (a type of CAR-T) in patients whose aggressive lymphoma has returned more than a year after their first treatment. It aims to see if this therapy can provide a strong and lasting response for this sp…

This early-phase trial is testing a combination treatment for adults with B-cell lymphomas that have come back or stopped responding to standard therapies. The approach involves giving patients a daily oral drug (pirtobrutinib) before and after an infusion of their own geneticall…

This early-stage trial is testing a new experimental drug called IKS03 in adults with advanced B-cell non-Hodgkin lymphomas that have returned or stopped responding to standard treatments. The study aims to find the safest and most effective dose by first testing increasing amoun…

This early-stage study is testing a personalized cell therapy called CAR-T for adults with certain blood cancers that have returned or not responded to at least two prior treatments. Doctors will collect a patient's own immune cells, genetically modify them to better target cance…

This study is testing whether adding the targeted drug zanubrutinib to standard chemotherapy (R-CHOP) works better for people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL) who have specific genetic markers. The trial will enroll about 21 adu…

This study looks back at a procedure called DEB-TACE to see if it is safe and helpful for people with a type of lymphoma that has come back or hasn't responded to other treatments. The procedure delivers chemotherapy beads directly to large tumors through their blood supply, aimi…

This study is testing if adding a new drug called selinexor to a standard chemotherapy regimen (R-CHOP) works better for people with a specific, harder-to-treat type of diffuse large B-cell lymphoma (DLBCL) that has a TP53 gene mutation. It will involve about 42 adults who have n…

This study is testing whether adding three new immunotherapy drugs (tafasitamab, retifanlimab, and rituximab) to standard chemotherapy is safe and effective for people newly diagnosed with aggressive B-cell lymphomas. The trial will enroll about 35 adults to see if this combinati…

This study is testing a modified stem cell transplant procedure to prevent lymphoma from spreading to the brain and spinal cord in high-risk patients. Researchers will enroll 36 adults with a specific type of aggressive lymphoma who have finished initial chemotherapy and are in r…

This is a first-in-human study testing a new type of personalized immune cell therapy (CAR-T cells) for adults with Non-Hodgkin Lymphoma that has come back or stopped responding to standard treatments. The main goal is to find a safe dose of these modified immune cells, which are…

This study is testing a two-part treatment for a type of blood cancer called diffuse large B-cell lymphoma that has come back or hasn't responded to standard chemotherapy. First, patients receive a short, intense course of radiation therapy. Then, they receive a personalized cell…

This study is testing a new type of personalized cell therapy for adults whose B-cell blood cancers have come back or not responded to standard treatments. The therapy, called CAR-T, is engineered to attack cancer cells using two targets (CD19 and CD20) instead of one, which may …

This study is testing whether adding an experimental drug called zilovertamab vedotin to standard chemotherapy works better than standard chemotherapy alone for adults whose diffuse large B-cell lymphoma has come back or hasn't responded to prior treatments. The main goals are to…

This early-stage study is testing a two-part treatment to prevent aggressive B-cell lymphoma from coming back after a stem cell transplant. Doctors take a patient's own immune cells, modify them to target cancer, and infuse them back. They then give a vaccine designed to boost th…

This study is testing whether giving radiation therapy once or twice daily works better for patients with aggressive lymphoma who are about to receive immune-based treatments. Researchers will treat different parts of the same tumor with different schedules to directly compare ef…

This study follows 700 adults with advanced lymphoma who are receiving epcoritamab treatment as prescribed by their doctors. Researchers will track how well the treatment works in real-world settings across 12-20 countries. Participants will be monitored for up to 3 years during …

This study aims to collect long-term safety and effectiveness data for patients with various blood cancers who are already taking the drug ibrutinib and benefiting from it. It provides continued access to the medication for about 700 participants who were in previous ibrutinib st…

This study is testing a combination of two drugs, acalabrutinib and rituximab, for older or frail adults newly diagnosed with an aggressive type of lymphoma called DLBCL. The goal is to see if this treatment is safe and effective for patients who are too weak for standard, more i…

This early-stage study is testing a new combination of six different targeted drugs for adults whose B-cell lymphoma has come back or hasn't responded to previous treatment. The main goal is to find the safest dose of this combination and see if it can help control the cancer. Re…

This study is testing a new oral medication called BGB-16673 for people with various B-cell cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe and effective dose and to see how well the drug shrinks tumors. It is for adults …

This early-stage study is testing a new, one-time gene therapy called VNX-101 for patients whose B-cell blood cancers have returned or not responded to other treatments. The therapy is designed to help the patient's own immune system continuously fight cancer cells. Researchers w…

This large study is testing whether adding a new drug called zilovertamab vedotin to standard lymphoma treatment helps people live longer without their cancer growing or spreading. Over 1,000 adults with newly diagnosed diffuse large B-cell lymphoma will receive either the new co…

This study tests whether adding personalized, gene-guided drugs to standard chemotherapy works better than standard therapy alone for people with untreated aggressive lymphoma. Researchers will compare two treatment groups in 152 Chinese patients to see which approach better cont…

This early-phase study is testing the safety and initial effectiveness of a new type of CAR-T cell therapy for adults with an aggressive form of lymphoma that has come back or not responded to at least two prior treatments. The therapy involves collecting a patient's own immune c…

This is a first-in-human study to find a safe and effective dose of a new drug called ONM-501. The drug is injected directly into tumors and is being tested alone and in combination with an approved immunotherapy drug (cemiplimab) in adults with advanced cancers that have stopped…

This study is testing a new drug, TQB2825, combined with standard chemotherapy for people with diffuse large B-cell lymphoma, a fast-growing blood cancer. It aims to see if the combination is safe and more effective at controlling the disease, especially for patients who are newl…

This is the first study in people testing an experimental oral drug called ABBV-525 for several types of advanced B-cell blood cancers, including lymphoma and leukemia. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it …

This study is testing whether a new drug combination (epcoritamab plus lenalidomide) works better than standard treatment for adults with aggressive lymphoma that has returned or hasn't responded to previous therapies. About 360 participants worldwide will receive either the new …

This early-stage study is testing a new antibody drug called AZD0486 in people with B-cell non-Hodgkin lymphoma that has returned or stopped responding to previous treatments. Researchers will give increasing doses to about 317 participants to find the safest amount and check for…

This study is testing a new drug called zilovertamab vedotin in children and young adults whose cancers have come back or haven't responded to standard treatments. It will enroll about 90 participants aged 1 year and older with specific blood cancers or solid tumors. The main goa…

This study is testing if adding a pill called acalabrutinib to standard chemotherapy can help more people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It is for adults who have not yet started any treatment for their lymphoma. Researchers …

This is the first study in people to test a new drug called ABBV-319 for several types of blood cancer that have come back or stopped responding to other treatments. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it mig…

This study is testing whether a drug called emapalumab can prevent severe side effects that sometimes occur with CAR-T cell therapy, a powerful treatment for certain lymphomas. Researchers will give emapalumab to 28 adults with hard-to-treat lymphoma who are receiving CAR-T thera…

This early-stage study is testing whether collecting a patient's own blood-forming stem cells and giving them back alongside CAR-T therapy is safe and feasible for people with aggressive blood cancers that have come back or not responded to other treatments. The main goals are to…

This study tests a modified version of a cell therapy (tisagenlecleucel) for patients with aggressive blood cancers when their manufactured treatment doesn't meet standard release specifications. It involves 200 children and adults with relapsed leukemia or lymphoma who have no o…

This study is testing if taking a daily pill called itacitinib for about a month before receiving a specialized cell therapy (CAR-T) can improve results for adults with an aggressive type of lymphoma. The researchers want to see if this approach helps control the cancer longer an…

This is an early-stage study testing the safety of a personalized cell therapy for adults with specific types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. Doctors will modify a patient's own immune cells to better target and fight their can…

This early-stage study is testing the safety and best dose of a new type of CAR-T cell therapy for adults whose diffuse large B-cell lymphoma has come back or not responded to other treatments. The therapy uses the patient's own modified immune cells, which are engineered to targ…

This study is testing if a special blood test can help doctors personalize treatment for a common type of lymphoma called DLBCL. The goal is to see if patients who show no signs of cancer in their blood halfway through standard chemotherapy can safely stop the chemo drugs early a…

This study is for adults with aggressive B-cell lymphoma that has returned or not responded to prior treatments. After receiving a standard CAR T-cell therapy, patients whose cancer is still present but stable will be assigned to receive one of two additional drugs, both drugs, o…

This is a first-in-human safety study testing a new personalized cell therapy called CLIC-2201. It is for adults and children with B-cell blood cancers (like leukemia and lymphoma) that have returned or not responded to other treatments. The main goal is to find the safest and mo…

This is a first-in-human study testing the safety and early effectiveness of a new cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T therapies. The main goa…

This study is testing a new combination of two drugs, nemtabrutinib and pembrolizumab, for patients with Richter transformation, a fast-growing type of lymphoma. The goal is to see if using these drugs together is safe and can shrink or control the cancer. The trial will enroll a…

This study aims to see how well and how safely a treatment called glofitamab works for Chinese adults whose aggressive lymphoma has come back or hasn't responded to their first treatment. It will follow 300 patients who are already planning to receive this therapy as part of thei…

This is a small, early-stage study for adults with B-cell leukemia or lymphoma that has come back or not responded to other treatments. The goal is to test the safety of a new two-step approach. First, patients receive a targeted radioactive drug (131-I apamistamab), followed by …

This study is testing a new method to find early signs that aggressive B-cell lymphoma might spread to the brain and spinal cord (central nervous system). Researchers will analyze spinal fluid from 50 high-risk patients using a sensitive DNA test to see if it can detect cancer ce…

This study aims to understand how specific genetic changes in a gene called MYC affect the course and treatment response of two aggressive types of B-cell lymphoma. Researchers will analyze tissue samples and medical records from 200 patients who have already been treated, lookin…

This study aims to understand how a cancer drug called venetoclax works in the body when it's given as a liquid made from crushed tablets. It will enroll up to 30 children and young adults with blood cancers who are already receiving this liquid form because they cannot swallow p…

This study aims to monitor the long-term health of 500 patients who have already received CAR-T cell therapy for various blood cancers in earlier trials. Researchers will follow these patients for up to 15 years to check for any late-developing side effects, such as new cancers o…

This study aims to find a blood test that can predict how well patients with a type of lymphoma will respond to CAR-T cell therapy. Researchers will look at a process called 'trogocytosis' in immune cells from 85 patients and some healthy volunteers. The goal is to identify early…

This study aims to understand how often lymphoma patients experience memory and thinking problems during and after chemotherapy. Researchers will track patients' cognitive function over time using standard tests and analyze spinal fluid in some patients to look for biological mar…

This study aims to understand how well lymphoma patients' immune systems respond to flu and COVID vaccines. Researchers will measure antibody levels and immune cells in 200 patients with various lymphoma types, comparing them over time. The goal is to learn how cancer treatments …

This study aims to learn more about a rare type of brain cancer called primary central nervous system lymphoma (PCNSL). Researchers will analyze blood samples from 20 people, including patients with this brain lymphoma, patients with a similar lymphoma elsewhere in the body, and …

This study aims to understand if CAR-T therapy, a powerful cancer treatment, reduces the body's long-term protection from common vaccines like measles, mumps, and tetanus. Researchers will observe 45 adults with blood cancers, measuring their antibody levels before and after CAR-…